Investigating how MIZ1 affects breast cancer outcomes in African American women
MIZ1 Activation in Triple-negative Breast Cancer Racial Disparities
This study is looking at why African American women with triple-negative breast cancer may have different outcomes compared to European American women, focusing on a specific factor called MIZ1 that seems to affect survival rates, with the hope of finding better treatment options for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11010395 on NIH RePORTER |
What this research studies
This research focuses on understanding the differences in triple-negative breast cancer (TNBC) outcomes between African American (AA) women and their European American counterparts. It aims to explore the role of MIZ1 activation in TNBC, which has been found to occur more frequently in AA tumors and is linked to poorer survival rates. By analyzing tumor samples from multiple patient cohorts, the study seeks to uncover the biological mechanisms behind these disparities and identify potential new treatment strategies targeting MIZ1 signaling. The ultimate goal is to improve clinical outcomes for AA women suffering from TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American women diagnosed with triple-negative breast cancer.
Not a fit: Patients who do not have triple-negative breast cancer or are not of African American descent may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for triple-negative breast cancer specifically tailored for African American women.
How similar studies have performed: Other research has shown promising results in understanding racial disparities in cancer outcomes, making this approach both relevant and potentially impactful.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Schiemann, William — Case Western Reserve University
- Study coordinator: Schiemann, William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.